๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

โœ Scribed by Eric J. Small; Linda J. Fippin; Mary Lou Ernest; Peter R. Carroll

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
622 KB
Volume
78
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

EIACKGROUND.

Many patients with advanced transitional cell carcinoma are unable to receive cisplatin-based therapy. The efficacy and toxicity of a carboplatin-based regimen in the treatment of patients with advanced transitional cell carcinoma was therefore evaluated.

METHODS.

Twenty-three patients with advanced transitional cell carcinoma were treated. Metastatic disease was present in 19 of 23 patients (83%) whereas 4 patients with T4, andlor N1, disease were treated. Patients were treated every 28 days with methotrexate, 30 mglm' intravenously (Lv.) on Days 1 and 15, along with leucovorin, 15 mglm' orally every 6 hours, 3 times daily beginning 24 hours after each methotrexate dose; vinblastine, 3 mg/m2 i.v. on Days 1 and 15; mitoxantrone, 15 ing/m2 i.v. on Day 1; and carboplatin, 300 mglm2 i.v. on Day 1, adjusted for creatinine clearance (MVNCa). Dosage in subsequent cycles was adjusted according to hematologic toxicity.

๐Ÿ“œ SIMILAR VOLUMES

A Phase II study of paclitaxel and ifosf
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium
โœ Christopher J. Sweeney; Stephen D. Williams; David E. Finch; Richard Bihrle; Ric ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 2 views

## BACKGROUND. Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated. METHODS. Ifosfamide 1.0 gm/m 2 on Days 1-4 and paclitaxel 135 mg/m 2 by 24-hour infusion on Day 4 were ad

A phase I clinical and pharmacologic stu
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
โœ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB ๐Ÿ‘ 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist

M- VAC or MVC for the treatment of advan
M- VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant
โœ Mark S. Soloway; Satoru Ishikawa; Tammy Taylor; Gilbert Ezell ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 579 KB

The cisplatin-based combination chemotherapy regimens of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after r

Treatment of patients with advanced gast
Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen : Two parallel randomized phase II studies
โœ Carlo Barone; Domenico C. Corsi; Carmelo Pozzo; Alessandra Cassano; Tecla Fontan ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 109 KB ๐Ÿ‘ 2 views

370 mg/m 2 , on Days 1-5 and 36 others in Study B received epirubicin, 30 mg/m 2 , cina Interna e Geriatria, Universita `Cattolica del on Days 1 and 5; etoposide, 100 mg/m 2 , on Days 1, 3, and 5; cisplatin, 30 mg/m 2 , S. Cuore, Rome, Italy. on Days 2 and 4; and lonidamine, 150 mg/day. ## RESULTS